

Eko.ai signs deals with AstraZeneca and Janssen for automating echocardiograms

29 September 2020 | News

eko.ai granted patent for automated heart ultrasound analysis workflow



eko.ai, a fast-growing, Sequoia India and EDBI backed, medtech startup based in Singapore using machine learning to automate the analysis of echocardiograms (echos), or ultrasound images of the heart, announced on World Heart Day several significant milestones, including renaming the company to Us2.ai.

Us2.ai is pleased to announce the grant of a US Patent No. 10,702,247 for its automated clinical workflow that recognizes and analyzes 2-dimensional and Doppler echo images for cardiac measurements and the diagnosis, prediction and prognosis of heart disease.

"Us2 software transforms what today is a slow, manual and error prone process into less than two minutes, one click and zero variability, delivering a complete echo report," said James Hare, CEO and co-founder of Us2.ai. "The potential of our AI platform has led to multiple research collaborations, and we're delighted to welcome both AstraZeneca and Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, as strategic partners in our mission to automate the fight against cardiovascular disease."

The collaboration with Janssen will focus on automating echocardiography analyses to facilitate identification of pulmonary hypertension. The AstraZeneca research collaboration will refine algorithms for the diagnosis of heart failure, as well as test access to automated echo analysis with point-of-care solutions for people with heart failure.

The company's decision support software is currently undergoing validation for regulatory review in multiple regions, and is available for research use.